Detalles de la búsqueda
1.
Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
Arterioscler Thromb Vasc Biol
; 44(6): 1447-1454, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38695169
2.
Factors Predicting Statin Initiation During Childhood in Familial Hypercholesterolemia: Importance of Genetic Diagnosis.
J Pediatr
; 253: 18-24.e2, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36049522
3.
PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction.
Nutr Metab Cardiovasc Dis
; 31(3): 880-885, 2021 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33546945
4.
Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey.
Lipids Health Dis
; 20(1): 45, 2021 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33947397
5.
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study.
Cardiovasc Drugs Ther
; 34(4): 515-523, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32363493
6.
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
Cardiovasc Diabetol
; 18(1): 71, 2019 06 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31164165
7.
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Arterioscler Thromb Vasc Biol
; 38(3): 592-598, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29284604
8.
No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data.
Eur Heart J
; 39(5): 374-381, 2018 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29186504
9.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
N Engl J Med
; 372(16): 1489-99, 2015 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-25773378
10.
Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience.
Curr Opin Lipidol
; 27(6): 597-604, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27755114
11.
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia.
Eur Heart J Suppl
; 18(Suppl C): C2-C12, 2016 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28533705
12.
Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.
Curr Cardiol Rep
; 18(7): 65, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27216845
13.
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
Eur Heart J
; 36(43): 2996-3003, 2015 Nov 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26330422
14.
Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.
Lipids Health Dis
; 14: 45, 2015 May 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-25985907
15.
Residual macrovascular risk in 2013: what have we learned?
Cardiovasc Diabetol
; 13: 26, 2014 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-24460800
16.
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.
Cardiovasc Drugs Ther
; 28(3): 281-9, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24842558
17.
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
BMC Cardiovasc Disord
; 14: 121, 2014 Sep 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25240705
18.
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.
Eur Heart J
; 39(14): 1131-1143, 2018 04 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29045644
19.
New prospects for PCSK9 inhibition?
Eur Heart J
; 39(27): 2600-2601, 2018 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29579192
20.
PCSK9 inhibitors.
Curr Opin Lipidol
; 24(3): 251-8, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23652470